12-Jun-2026
No press releases found.
(Exclusive) PRO Biotech Letter: Market Dislocation, Gilead, Corona-Portunities
Seeking Alpha (Sun, 7-Feb 2:28 AM ET)
Vanguard overtakes BlackRock as largest ETF issuer - Bloomberg
Seeking Alpha News (Fri, 12-Jun 8:19 AM ET)
As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation?
Seeking Alpha News (Wed, 10-Jun 3:19 PM ET)
We now live in a world of rolling bubbles – analyst
Seeking Alpha News (Wed, 10-Jun 12:26 PM ET)
The iShares Biotechnology ETF seeks to track the investment results of an index composed of U.S.-listed equities in the biotechnology sector. It provides exposure to U.S. companies in the biotechnology industry.
iShares Biotechnology ETF trades on the NASDAQ stock market under the symbol IBB.
As of June 12, 2026, IBB stock price climbed to $170.66 with 1,674,580 million shares trading.
IBB has a beta of 0.79, meaning it tends to be less sensitive to market movements. IBB has a correlation of 0.27 to the broad based SPY ETF.
IBB has a market cap of $8.01 billion. This is considered a Mid Cap stock.
In the last 3 years, IBB traded as high as $179.64 and as low as $107.43.
IBB has outperformed the market in the last year with a price return of +32.6% while the SPY ETF gained +24.1%. However, in the short term, IBB had mixed performance relative to the market. It has underperformed in the last 3 months, returning +2.7% vs +11.6% return in SPY. But in the last 2 weeks, IBB shares have fared better than the market returning -0.9% compared to SPY -1.9%.
IBB support price is $167.80 and resistance is $173.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IBB shares will trade within this expected range on the day.